The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Although biological disease-modifying antirheumatic disease drugs (bDMARDs) have represented a paradigm shift in the treatment of rheumatoid arthritis (RA), their high cost is a burden for patients...